Dr. Reddy's Laboratories Limited — Important, 25-07-2025: General Updates

Dr. Reddy's Laboratories has deployed Rs. 565.41 Cr into DRL Russia, its wholly-owned step-down subsidiary. This capital injection is earmarked for DRL Russia's working capital requirements. Operating as a pharmaceutical distributor in Russia, DRL Russia reported strong revenue growth: Rs. 2,347 Cr in FY2025, Rs. 2,084 Cr in FY2024, and Rs. 1,915 Cr in FY2023. This strategic investment supports the subsidiary's continued operations and expansion in the Russian market.